DUBLIN, Ireland, February 9, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the year to

DUBLIN, October 28, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to September

DUBLIN, October 29, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2010. Financial Highlights Q3 2010(2) Product sales(1) $794 million +32% Total revenues $874 million +31% Non GAAP operating income $298 million +123% US GAAP operating income $156 million +70% Non GAAP diluted earnings per ADS $1.16 +138% US GAAP diluted earnings per ADS $0.52 +59% (1) Product sales excluding ADDERALL XR ("Core Product Sales") were up 31% to $694 million.

CAMBRIDGE, Massachusetts, September 9, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB (ActRIIB) class of molecules being developed by Acceleron Pharma Inc., a private biotechnology company based in Cambridge, Massachusetts.

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 1 clinical study of ACE-031, its lead compound for treating diseases involving the loss of muscle mass and function.